company background image
0IGA logo

Emergent BioSolutions LSE:0IGA Stock Report

Last Price

US$8.69

Market Cap

US$472.7m

7D

-5.9%

1Y

247.6%

Updated

13 Oct, 2024

Data

Company Financials +

Emergent BioSolutions Inc.

LSE:0IGA Stock Report

Market Cap: US$472.7m

0IGA Stock Overview

A life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States.

0IGA fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Emergent BioSolutions Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Emergent BioSolutions
Historical stock prices
Current Share PriceUS$8.69
52 Week HighUS$15.10
52 Week LowUS$1.48
Beta1.59
11 Month Change10.53%
3 Month Change-24.32%
1 Year Change247.60%
33 Year Change-83.29%
5 Year Change-84.60%
Change since IPO-82.89%

Recent News & Updates

Recent updates

Shareholder Returns

0IGAGB BiotechsGB Market
7D-5.9%0.8%-0.5%
1Y247.6%-17.6%7.7%

Return vs Industry: 0IGA exceeded the UK Biotechs industry which returned -17.6% over the past year.

Return vs Market: 0IGA exceeded the UK Market which returned 7.7% over the past year.

Price Volatility

Is 0IGA's price volatile compared to industry and market?
0IGA volatility
0IGA Average Weekly Movement27.0%
Biotechs Industry Average Movement8.5%
Market Average Movement4.6%
10% most volatile stocks in GB Market9.3%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0IGA's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0IGA's weekly volatility (27%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
19981,600Joe Papawww.emergentbiosolutions.com

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector.

Emergent BioSolutions Inc. Fundamentals Summary

How do Emergent BioSolutions's earnings and revenue compare to its market cap?
0IGA fundamental statistics
Market capUS$472.67m
Earnings (TTM)-US$587.00m
Revenue (TTM)US$1.10b

0.4x

P/S Ratio

-0.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0IGA income statement (TTM)
RevenueUS$1.10b
Cost of RevenueUS$883.80m
Gross ProfitUS$218.40m
Other ExpensesUS$805.40m
Earnings-US$587.00m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-10.87
Gross Margin19.81%
Net Profit Margin-53.26%
Debt/Equity Ratio223.2%

How did 0IGA perform over the long term?

See historical performance and comparison